These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 3731947)
41. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin. Edelstein M; Vietti T; Valeriote F Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905 [No Abstract] [Full Text] [Related]
42. Testing of 2,3-dihydro-1,3-6H-oxazine-dione (3-oxauracil) in mouse L1210 leukemia and 37 sarcoma. Stoychkov JN; Mircheva JJ Cancer Treat Rep; 1978 Dec; 62(12):2121-3. PubMed ID: 751720 [TBL] [Abstract][Full Text] [Related]
43. Effect of "3-oxauracil" (2,3-dihydro-1,3-6H-oxazine-dione) in L1210 leukemia. Ujházy V; Reiner P; Farkas J; Skoda J Neoplasma; 1977; 24(3):259-61. PubMed ID: 895936 [TBL] [Abstract][Full Text] [Related]
44. The influence of schedule of administration of mitomycin C (NSC-26980) in the treatment of L1210 leukemia. Kojima R; Goldin A; Mantel N Cancer Chemother Rep 2; 1972 Nov; 3(1):111-9. PubMed ID: 4660730 [No Abstract] [Full Text] [Related]
45. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia. Klubes P; Cerna I Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161 [TBL] [Abstract][Full Text] [Related]
46. Chronochemotherapy: L 1210 leukemia and beyond. Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097 [TBL] [Abstract][Full Text] [Related]
47. Influence of pentagastrin administration on survival of mice with L1210 leukemia. Armata J; Srebo Z; Stankiewicz D; Wiliński B Cancer Treat Rep; 1983 Apr; 67(4):408. PubMed ID: 6850660 [No Abstract] [Full Text] [Related]
48. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo. Guo QL; Wu MS; Chen Z Acta Pharmacol Sin; 2002 Oct; 23(10):946-51. PubMed ID: 12370101 [TBL] [Abstract][Full Text] [Related]
49. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines. Fuji H Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299 [TBL] [Abstract][Full Text] [Related]
50. [Disruption of DNA synthesis and structure of mouse L1210 leukemia cells, sensitive and resistant to 1-methyl-1 nitrosourea and 1,3-bis(2-chloroethyl)-1-nitrosourea in vivo]. Kukushkina GV; Peretolchina NM; Minenkova EA; Verovskiĭ VN; Sof'ina ZP Biokhimiia; 1984 Jul; 49(7):1189-98. PubMed ID: 6477985 [TBL] [Abstract][Full Text] [Related]
51. Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16. Slater LM; Stupecky M; Sweet P; Osann KE Leuk Res; 2002 Feb; 26(2):203-6. PubMed ID: 11755470 [TBL] [Abstract][Full Text] [Related]
52. On methods for testing and achieving cancer chronotherapy. Halberg F; Nelson W; Cornelissen G; Haus E; Scheving LE; Good RA Cancer Treat Rep; 1979 Aug; 63(8):1428-30. PubMed ID: 476717 [No Abstract] [Full Text] [Related]
53. Antitumor effects of ribavirin on L1210 leukemia in the DBA/2 mouse. Jolley WB; Chu WT; Salter JM; Hinshaw DB; Randhawa AS Ann N Y Acad Sci; 1977 Mar; 284():585-90. PubMed ID: 280149 [No Abstract] [Full Text] [Related]
54. Pepstatin, an ascites retardant of L1210 tumor-bearing mice. Greenbaum LM; Semente G J Natl Cancer Inst; 1977 Jul; 59(1):259-62. PubMed ID: 875057 [TBL] [Abstract][Full Text] [Related]
55. Circadian dependence of host and tumor responses to cyclophosphamide in mice. Cardoso SS; Avery T; Venditti JM; Goldin A Eur J Cancer (1965); 1978 Sep; 14(9):949-54. PubMed ID: 710487 [No Abstract] [Full Text] [Related]
56. Effect of zinc administration on the growth of L1210 and BW5147 tumors in mice. Phillips JL; Sheridan PJ J Natl Cancer Inst; 1976 Aug; 57(2):361-3. PubMed ID: 1003517 [TBL] [Abstract][Full Text] [Related]